The management of inhibitors in haemophilia A: Introduction and systematic review of current practice

Haemophilia

Volumn 9, Issue 4, 2003, Pages 405-417

  Paisley, S ^a   Wight, J ^a   Currie, E ^b   Knight, C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

Current practice; Factor VIII; Guidelines; Haemophilia A; Inhibitors; Systematic review

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY PRODUCTION; BLEEDING; CLINICAL PRACTICE; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INHIBITION; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; MEDICAL LITERATURE; MOLECULAR RECOGNITION; MUSCLE BLEEDING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; UNITED KINGDOM;

EID: 0037810801     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00779.x     Document Type: Review

References (31)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
2. Wight J, Paisley J, Knight C. Immune tolerance induction (ITI) in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436-63.
3. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
4. Knight C, Paisley S, Wight J, Lloyd Jones M. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
5. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying out or Commissioning Reviews (CRD Report 4) 2nd edn. York: NHS Centre for Reviews and Dissemination, University of York, 2001.
6. Hay CR, Colvin BT, Ludlam CA, Hill FG, Preston FE. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagul Fibrinolysis 1996; 7: 134-8.
7. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
8. Rubinger M, Rivard GE, Teitel J, Walker I. Suggestions for the management of factor VIII inhibitors. Haemophilia 2000; 6 (Suppl. 1): 52-9.
9. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5: 203-6.
10. Santagostino E, Mannucci PM, Bianchi BA. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
11. Gringeri A. Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE). Haemophilia 1998; 4: 423-4.
12. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee members. Vox Sang 1999; 77 (Suppl. 1): 31-2.
13. Haya S, Lopez MF, Aznar JA, Battle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
14. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
15. Mariani G, Scheibel E, Nogao T et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31 (2 Suppl. 4): 62-4.
16. Ghirardini A, Puopolo M, Chiarotti F, Mariani G. The international registry of immune tolerance: 1994 update. Vox Sang 1996; 70 (Suppl. 1): 42-6.
17. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 (Suppl. 1): 25-7.
18. Mariani G, Kroner B, ITSG. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologia 2001; 86: 1186-93.
19. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
20. Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56-9.
21. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
22. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
23. Berntorp E, Astermark J, Carlborg E. Malmo protocol update. Haematologica 2000; 85 (Suppl. 10): 48-51.
24. Carlborg E, Astermark J, Lethagen S, Ljung R, Berntorp E. The Malmo model for immune tolerance induction: impact of previous treatment on outcome. Haemophilia 2000; 6: 639-42.
25. Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ, Kok AJ, Sjamsjoedin-Visser EJ, Sixma JJ. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291-7.
26. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
27. Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Treatment protocols in The Netherlands. Haemophilia 1998; 4: 428-30.
28. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-95.
29. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn protocol'. Vox Sang 1996; 70 (Suppl. 1): 30-5.
30. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (Suppl. 1): 49-54.
31. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-8.